Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Effectiveness of antiviral treatment for Hepatitis C virus infection in adults

This month's publication of the Annals of Internal Medicine compares the effectiveness of antiviral treatment for Hepatitis C virus infection in adults.

News image

Dr Roger Chou and colleagues compared benefits and harms of antiviral regimens for chronic HCV infection in treatment-naive adults.

The team searched for English-language literature from MEDLINE, the Cochrane Library Database, Embase, Scopus, PsychINFO, and clinical trial registries.

The research team identified randomized trials of antiviral treatments, and cohort studies examining associations between sustained virologic response after therapy and clinical outcomes.

Several investigators abstracted study details and quality by using predefined criteria.

The researchers noted that no trial evaluated effectiveness of treatment on long-term clinical outcomes.

PEG-interferon alfa-2b plus ribavirin was associated with a lower sustained virologic response
Annals of Internal Medicine

Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a lower likelihood of sustained virologic response than was pegylated interferon alfa-2a plus ribavirin.

For genotype 2 or 3 infection, dual therapy for 12 to 16 weeks was associated with a lower likelihood of sustained virologic response than was therapy for 24 weeks, and lower doses of pegylated interferon alfa-2b were less effective than standard doses.

The doctors found that for genotype 1 infection, fair-quality trials reported that triple therapy with pegylated interferon, ribavirin, and either boceprevir or telaprevir was associated with a higher likelihood of sustained virologic response than was dual therapy.

Compared with dual therapy, boceprevir triple therapy increased risk for hematologic adverse events, and telaprevir triple therapy increased risk for anemia and rash.

The research team noted that a large well-designed cohort study and 18 smaller cohort studies found that an sustained virologic response after antiviral therapy was associated with lower risk for all-cause mortality than was no sustained virologic response.

Trials involved highly selected populations.

The team found that observational studies did not always adequately control for confounders.

Dr Chou's team commented, "Sustained virologic response rates for genotype 1 infection are higher with triple therapy that includes a protease inhibitor than with standard dual therapy."

"A sustained virologic response after antiviral therapy appears associated with improved clinical outcomes." 

Ann Intern Med 2013; 158(2): 114-123
28 January 2013

Go to top of page Email this page Email this page to a colleague

 23 July 2014

Advanced search
 23 July 2014 
C-section and IBD risk
 23 July 2014 
Sofosbuvir and ribavirin for Hep C
 23 July 2014 
Early corticosteroids after the diagnosis of ulcerative colitis
 22 July 2014 
Alcohol and colorectal adenoma risk
 22 July 2014 
Cognitive behavioral therapy in IBS
 22 July 2014 
Thromboembolism in IBD
 21 July 2014 
Mortality in IBD
 21 July 2014 
Stents to prevent post-ERCP pancreatitis
 21 July 2014 
Psychometric validation of IBS symptom severity
 18 July 2014 
ERCP with overtube-assisted enteroscopy
 18 July 2014 
Treatment of enteropancreatic neuroendocrine tumors
 18 July 2014 
Ulcer complications and dyspeptic symptoms
 17 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 17 July 2014 
Treatment of H. pylori
 17 July 2014 
Ultrasound for diagnosis of gastric varices
 16 July 2014 
Mortality after colectomy in IBD
 16 July 2014 
Esophageal cancer missed at endoscopy
 16 July 2014 
Screening for Hepatitis B
 15 July 2014 
Diagnosing diverticulitis
 15 July 2014 
Variation in management decisions for colorectal cancer
 15 July 2014 
Muscle cramps in cirrhosis
 14 July 2014 
Predicting the course of ulcerative colitis
 14 July 2014 
Choice in colorectal cancer screening tests
 14 July 2014 
Adhesions in abdominal surgery
 11 July 2014 
Temporal evolution of antidrug antibodies in IBD
 11 July 2014 
Atopy and functional gastrointestinal disorders
 11 July 2014 
Fecal microbiota transplant for C. diff
 10 July 2014 
Acid-suppressive medications and cancer risk in Barrett's
 10 July 2014 
Personalized medicine in the management of IBD
 10 July 2014 
Pregnancy outcome in anti-TNF treated women with IBD
 09 July 2014 
Quality of care provided to patients with varices
 09 July 2014 
Eosinophilic esophagitis and celiac disease
 09 July 2014 
Diagnosis and management of adult celiac disease
 08 July 2014 
Screening for Hep B
 08 July 2014 
NSAID-induced small intestinal injury
 08 July 2014 
Drug-induced liver injury
 07 July 2014 
Pediatric celiac disease risk factors
 07 July 2014 
Obesity and complications after lapaproscopic colorectal surgery
 07 July 2014 
Everolimus and advanced hepatocellular carcinoma
 04 July 2014 
Day-case vs inpatient laparoscopic fundoplication
 04 July 2014 
Alcohol assessment in liver transplant
 04 July 2014 
Clinical competence in colorectal cancer surgery
 03 July 2014 
Predicting acute liver failure in drug-induced liver injury
 03 July 2014 
Cognitive dysfunction impairs quality of life after liver transplant
 03 July 2014 
NOTES for colon resections
 02 July 2014 
Routine colonoscopy for uncomplicated diverticulitis
 02 July 2014 
Risk of stroke in ulcerative colitis
 02 July 2014 
Hemodialysis during liver transplant
 01 July 2014 
Outcomes for pregnant women with primary biliary cirrhosis
 01 July 2014 
Liver-prognosis assessment in Hep C
 01 July 2014 
Mortality from biliary diseases requiring ERCP
 30 June 2014 
Combination therapy for eradication of Helicobacter pylori
 30 June 2014 
Drug-induced liver injury
 30 June 2014 
Surrogate for adenoma detection rate
 27 June 2014 
Infliximab and luminal pediatric Crohn's
 27 June 2014 
Colonoscopy surveillance intervals
 27 June 2014 
Endoscopy protocol for serrated polyposis syndrome
 26 June 2014 
Cognitive impairment in celiac disease
 26 June 2014 

Congenital malformations in offspring of parents with celiac disease

 26 June 2014 
Risk of colorectal adenomas and glucose metabolism

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us